About encorafen ib
BRAF kinase inhibitor
Used for
- Treats certain BRAF V600E-mutated cancers, including melanoma, colorectal cancer, and non-small-cell lung cancer, with other medicines.
Usual adult dose
Melanoma: 450 mg once daily with binimetinib. Colorectal cancer: 300 mg once daily with cetuximab, sometimes with chemotherapy. Lung cancer: 450 mg once daily with binimetinib.
Common side effects
- Tiredness, nausea, vomiting, diarrhea, and abdominal pain
- Joint pain, muscle problems, or headache
- Skin rash, thickened skin, or hair loss
- Liver test changes
Important warnings
- Can cause new skin cancers; skin checks are needed during and after treatment.
- May cause eye problems, heart dysfunction, bleeding, or severe muscle injury.
- Can harm an unborn baby; effective contraception is required during treatment and afterward.
- Treatment and dose depend on cancer type, mutation testing, and combination medicines.
Pregnancy
May harm an unborn baby. Avoid during pregnancy; effective contraception is advised during treatment and for two weeks afterward.
Breastfeeding
Do not breastfeed during treatment or for two weeks after the last dose.
Interactions
- Strong or moderate CYP3A4 inhibitors can increase encorafenib levels.
- Strong or moderate CYP3A4 inducers can reduce effectiveness.
- May affect levels of medicines metabolized by CYP3A4, CYP2C9, or CYP2C19.
- QT-prolonging medicines may increase abnormal heart-rhythm risk.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.